Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc. Identifier:
First received: December 17, 2009
Last updated: March 30, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2010
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 16, 2015